Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Two-part prodrug system activates immune attack only in tumor's unique environment

2.

After all, Pulled Myeloma Drug May Help Treat the Illness.

3.

Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL

4.

A Chemo-Free Option for Some Advanced Endometrial Cancers?

5.

No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot